CuraSen Therapeutics

OverviewSuggest Edit

CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases. The Company's products are used for curing Parkinson’s Disease, Alzheimer’s Disease, and less common neurodegenerative disorders.

TypePrivate
Founded2016
HQSan Carlos, CA, US
Websitecurasen.com

Latest Updates

Employees (est.) (Jan 2022)14(-6%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

CuraSen Therapeutics Office Locations

CuraSen Therapeutics has an office in San Carlos
San Carlos, CA, US (HQ)
930 Brittan Ave #306
Show all (1)

CuraSen Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

CuraSen Therapeutics total Funding

$54.5 m

CuraSen Therapeutics latest funding size

$54.5 m

Time since last funding

3 years ago

CuraSen Therapeutics investors

CuraSen Therapeutics's latest funding round in October 2018 was reported to be $54.5 m. In total, CuraSen Therapeutics has raised $54.5 m
Show all financial metrics

CuraSen Therapeutics Online and Social Media Presence

Embed Graph

CuraSen Therapeutics Blogs

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

Increased Cerebral Blood Flow is Correlated with Increased Neuronal Activity and Cognitive Efficacy Signals Data Presented at the 14th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference November 9, 2021 – Boston, MA and San Carlos, CA – CuraSen Therapeutics, Inc, a clinical-stage compan…

CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease

Data Presented at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 21) Highlight Potential of Beta Adrenoceptor Agonists toTreat Neurodegenerative Disease March 15, 2021 – San Carlos, CA – CuraSen Therapeutics, Inc., a privately held, clinical-stage biotechnology comp…

Renee Martin, PhD

Dr. Martin joined CuraSen in 2020 bringing more than 25 years of experience in the pharmaceutical industry, spanning target assessment through Phase 3 clinical trials in indications from neuroscience through inflammation.  Previously, she was Senior Vice President of Medical Sciences at Anthera Phar…

Wei Chen, PhD

Dr. Chen joined CuraSen in November 2018, bringing more than 15 years in industry experience in drug discovery and chemistry. Previously, he spent more than 10 years at Pharmacyclics, where he was most recently executive director, medicinal chemistry and early process development. During his tenure …

CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations

September 10, 2019—San Mateo, Calif.—CuraSen Therapeutics, Inc., a privately held clinical stage biotechnology company focused on developing therapies to treat neurodegenerative diseases, has appointed Peter Butera as senior vice president, operations. Mr. Butera brings more than 30 years of diverse…

CuraSen Therapeutics Frequently Asked Questions

  • When was CuraSen Therapeutics founded?

    CuraSen Therapeutics was founded in 2016.

  • How many employees does CuraSen Therapeutics have?

    CuraSen Therapeutics has 14 employees.

  • Who are CuraSen Therapeutics competitors?

    Competitors of CuraSen Therapeutics include Apotheekzorg Bladel, Porton Biopharma and Laboratorios VALMOR.

  • Where is CuraSen Therapeutics headquarters?

    CuraSen Therapeutics headquarters is located at 930 Brittan Ave #306, San Carlos.

  • Where are CuraSen Therapeutics offices?

    CuraSen Therapeutics has an office in San Carlos.

  • How many offices does CuraSen Therapeutics have?

    CuraSen Therapeutics has 1 office.